Literature DB >> 8743185

Monoclonal antibodies to human fibrin: interaction with other animal fibrins.

T Edgell1, F McEvoy, P Webbon, P J Gaffney.   

Abstract

Four monoclonal antibodies have previously been raised in our laboratory for possible use in thrombus imaging and the targeting of thrombolytic agents. These antibodies were raised to various human fibrin-related immunogens and each antibody had been selected for its specificity towards fibrin and not fibrinogen. To study further these antibodies in animal circulation models both in vivo and in vitro, their selectivity towards human fibrin as opposed to other animal fibrins was examined. In this study dissociation constants for each antibody with each of six species fibrins (human, baboon, pig, dog, sheep and rabbit) were estimated using both fibrin clots and monolayers. Some limited data were also obtained with Sepharose-fibrin. Of the antibodies two (denoted 12B3B10 and 12B3A11) are seen to bind almost exclusively to human fibrin with dissociation constants of about 8 x 10(-10) M using fibrin clots and monolayers. These same two mabs bound to baboon fibrin with a dissociation constant of 2 x 10(-9) M, while neither displayed significant levels of binding to the fibrins from dog, pig, sheep and rabbit. The other two antibodies investigated (1H10 and 5F3) were found to bind well to fibrins of human, baboon, pig and dog, with dissociation constants in the range of 1.4-4.2 x 10(-9) M. However neither 1H10 nor 5F3 displayed significant recognition of sheep and rabbit fibrins. Both 1H10 and 5F3 were also found by means of competitive ELISA's to retain their selectivity to baboon, dog and pig fibrins in the presence of their respective fibrinogens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8743185

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Targeted PARACEST nanoparticle contrast agent for the detection of fibrin.

Authors:  Patrick M Winter; Kejia Cai; Junjie Chen; Christopher R Adair; Garry E Kiefer; Phillip S Athey; Patrick J Gaffney; Carolyn E Buff; J David Robertson; Shelton D Caruthers; Samuel A Wickline; Gregory M Lanza
Journal:  Magn Reson Med       Date:  2006-12       Impact factor: 4.668

Review 2.  Rationale for a nanomedicine approach to thrombolytic therapy.

Authors:  Gregory M Lanza; Jon N Marsh; Grace Hu; Michael J Scott; Anne H Schmieder; Shelton D Caruthers; Dipanjan Pan; Samuel A Wickline
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

3.  Lipid contribution to the affinity of antigen association with specific antibodies conjugated to liposomes.

Authors:  Melvin E Klegerman; Shaoling Huang; Devang Parikh; Janet Martinez; Sasha M Demos; Hayat A Onyuksel; David D McPherson
Journal:  Biochim Biophys Acta       Date:  2007-04-14

4.  In vivo volumetric intravascular ultrasound visualization of early/inflammatory arterial atheroma using targeted echogenic immunoliposomes.

Authors:  Hyunggun Kim; Melanie R Moody; Susan T Laing; Patrick H Kee; Shao-Ling Huang; Melvin E Klegerman; David D McPherson
Journal:  Invest Radiol       Date:  2010-10       Impact factor: 6.016

Review 5.  An unmet clinical need: The history of thrombus imaging.

Authors:  Gregory M Lanza; Grace Cui; Anne H Schmieder; Huiying Zhang; John S Allen; Michael J Scott; Todd Williams; Xiaoxia Yang
Journal:  J Nucl Cardiol       Date:  2017-06-12       Impact factor: 5.952

6.  A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke.

Authors:  Jon N Marsh; Grace Hu; Michael J Scott; Huiying Zhang; Matthew J Goette; Patrick J Gaffney; Shelton D Caruthers; Samuel A Wickline; Dana Abendschein; Gregory M Lanza
Journal:  Nanomedicine (Lond)       Date:  2011-04-20       Impact factor: 5.307

7.  Temperature-sensitive liposome-mediated delivery of thrombolytic agents.

Authors:  Vishal Saxena; Carmen Gacchina Johnson; Ayele H Negussie; Karun V Sharma; Matthew R Dreher; Bradford J Wood
Journal:  Int J Hyperthermia       Date:  2015-03-13       Impact factor: 3.914

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.